Table 1 Age, gender and MS status for subjects with POLE/POLD1 variants or POLE/POLD1 WT in this study.

From: Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population

Clinicopathologic Factor

Number of patients (%)

P

POLE&POLD1 WT

POLE Neu Var

P

POLD1 Neu Var

P

POLE Dam Var

P

POLD1 Dam Var

Age

≥60

47 (60.3)

11 (57.9)

0.524

8 (44.4)

0.448

7 (25.9)

0.002

8 (57.1)

0.93

<60

31 (39.7)

5 (26.3)

 

8 (44.4)

 

20 (74.1)

 

5 (35.7)

 

≥50

62 (79.5)

13 (68.4)

1

13 (72.2)

1

15 (55.6)

0.015

10 (71.4)

1

<50

16 (20.5)

3 (15.8)

 

3 (16.7)

 

12 (44.4)

 

3 (21.4)

 

≥40

74 (94.9)

16 (84.2)

1

15 (83.3)

1

21 (77.8)

0.026

11 (78.6)

0.2

<40

4 (5.1)

0 (0)

 

1 (5.6)

 

6 (22.2)

 

2 (14.3)

 

unkown

0 (0)

3 (15.8)

 

2 (11.1)

 

0 (0)

 

1 (7.1)

 

Gender

female

36 (46.2)

6 (31.6)

0.526

7 (38.9)

0.86

11 (40.7)

0.626

5 (35.7)

0.77

male

42 (53.8)

10 (52.6)

 

9 (50.0)

 

16 (59.3)

 

7 (50.0)

 

unkown

0 (0)

3 (15.8)

 

2 (11.1)

 

0 (0)

 

2 (14.3)

 

MS status

MSS

50 (64.1)

6 (31.6)

0.124

5 (27.8)

0.357

15 (55.6)

1

4 (28.6)

0

MSI

3 (3.8)

2 (10.5)

 

1 (5.6)

 

1 (3.7)

 

4 (28.6)

 

unkown

25 (32.1)

11 (57.9)

 

12 (66.7)

 

11 (40.7)

 

6 (42.9)

 
  1. WT = wild type; Neu = neutral; Var = variant; Dam = damaging; MS = microsatellite; MSS = microsatellite stable; MSI = microsatellite instable.
Back to article page